Analyst firms · Morgan Stanley · AARD
Morgan Stanley AARD price target and rating history
Aardvark Therapeutics Inc. (AARD) · Health Care
Morgan Stanley rates Aardvark Therapeutics Inc. (AARD) Underweight with a $3 price target, as of its latest action on May 15, 2026. It has published 3 rating actions on AARD since March 2025, including 0 upgrades and 2 downgrades. Across 6 firms with a AARD price target in the last 12 months, the median target is $19. Morgan Stanley's $3 is 84% below that.
- Current rating
- Underweight
- Price target
- $3
- Median target, all firms
- $19
- Actions on AARD
- 3
Morgan Stanley price target on AARD
Every Morgan Stanley rating on AARD
- May 15, 2026
- Mar 2, 2026
- Mar 10, 2025
How other firms rate AARD
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Raymond James | Mkt Perform | $47 | Nov 5, 2026 |
| Morgan Stanley | Underweight | $3 | May 15, 2026 |
| Stifel | Hold | $6 | Mar 2, 2026 |
| RBC Capital Markets | Sector Perform | $6 | Mar 2, 2026 |
| H.C. Wainwright | Neutral | Mar 2, 2026 | |
| B. Riley Securities | Buy | $32 | Jan 28, 2026 |
| Oppenheimer | Outperform | $35 | Dec 23, 2025 |
| William Blair | Outperform | Dec 12, 2025 |
Questions about Morgan Stanley and AARD
- What is Morgan Stanley's price target for AARD?
- Morgan Stanley's latest stated price target for Aardvark Therapeutics Inc. (AARD) is $3, from its action on May 15, 2026.
- What is Morgan Stanley's rating on AARD?
- Morgan Stanley rates AARD Underweight, a bearish rating, as of May 15, 2026.
- When did Morgan Stanley last change its view on AARD?
- On May 15, 2026, Morgan Stanley downgrades to Underweight from Equal-Weight, price target $3.
- How does Morgan Stanley's AARD target compare with other analysts?
- Across 6 firms with a AARD price target in the last 12 months, the median target is $19. Morgan Stanley's $3 is 84% below that.
All Morgan Stanley ratingsAARD news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.